Stockwinners Market Radar for June 06, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:01 EDT Cathie Wood's ARK Investment bought 137K shares of Intellia Therapeutics today

19:50 EDT DBV Technologies trading halted, news pending

19:50 EDT Volcon Inc trading halted, news pending

19:10 EDT Opthea Ltd (ADR) trading halted, news pending

18:24 EDT Lyft CEO: Operational excellence is our goal - In an interview on CNBC's Mad Money, David Risher said Lyft has more drivers on the platform now than at any time in the company's history. It has started to focus on Canada over the past six months and results are promising, he noted. The company is exploring partnerships and a "price lock" feature for daily commuters. He expects mechanical drivers to come onto the platform "someday," but not near term.

17:56 EDT Deckers Outdoor CEO David Powers sells almost $12M in shares - The CEO of Deckers Outdoor David Powers sold 10,955 sjhares of company stock at $1,086.50 per share on June 6, for a total transaction amount of $11,902,608.

17:03 EDT McKesson CEO sells $2.16M in common stock - In a regulatory filing, McKesson disclosed that its CEO Brian Tyler sold 3.75K shares of common stock on June 5th in a total transaction size of $2.16M.

17:00 EDT Saba announces update on 1-for-2 reverse stock split - Saba Capital Income & Opportunities Fund II announced an update on the 1-for-2 reverse stock split of the Fund's common shares that was approved by its Board of Trustees. The Reverse Split is expected to become effective immediately after the close of trading on the NYSE on June 21, 2024, and the Fund's common shares are expected to begin trading on the NYSE on a reverse split-adjusted basis at the open of trading on June 24, 2024. As of the Effective Date, every two shares of the Fund's issued and outstanding common shares will be converted into one common share. The Fund's common shares will continue to trade on the NYSE under the symbol "SABA," and the new CUSIP number for the Fund's common shares will be 880198205 following the Reverse Split. The Fund has also adopted an updated managed distribution plan. In connection with the Reverse Split, the Fund's fixed monthly distribution will be adjusted from $0.029 per share to $0.058 per share, beginning with the first distribution to be declared following the Effective Date of the Reverse Split. Such adjustment to the Fund's fixed monthly distribution will result in no change in monthly cash flow to shareholders.

16:46 EDT DocuSign falls 6% to $51.10 after Q1 results, FY25 guidance

16:36 EDT iPower enhances SuperSuite platform with Amazon Logistics Services - iPower (IPW) announced the integration of Amazon (AMZN) Logistics Services into the company's SuperSuite platform. iPower will leverage Amazon Logistics Services to bolster its last mile delivery capabilities, enhancing a critical component of SuperSuite's comprehensive supply chain offerings. This collaboration will enable SuperSuite clients to deliver products with the speed, reliability, and efficiency that Amazon is renowned for, adding further depth to SuperSuite's value proposition. Key benefits of this integration include Competitive Rates: Amazon Logistics Services offers competitive rates on certain types of services, reducing costs for SuperSuite partners.

16:34 EDT Samsara falls 7% to $32.52 following Q1 report, fiscal 2025 outlook

16:30 EDT WisdomTree says Egan-Jones recommends holders vote for company's board nominees - WidsomTree announced that Egan-Jones Ratings Co., an independent proxy advisory firm, has recommended that stockholders vote "FOR" all company-recommended proposals, including all nine members of WisdomTree's Board of Directors, at WisdomTree's 2024 Annual Meeting of Stockholders. Win Neuger, Chair of the WisdomTree Board of Directors, said, "We are pleased that, like Institutional Shareholder Services and Glass Lewis, Egan-Jones recognizes WisdomTree's strong performance and robust corporate governance practices. Importantly, Egan-Jones emphasizes the successful execution of WisdomTree's strategy so far, especially through the hard work of the Company's management and Board."

16:27 EDT FuelCell discloses Nasdaq listing requirement notice - The company states: "On May 31, 2024, FuelCell Energy received written notice from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that it is not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price of the Company's common stock was below the required minimum of $1.00 per share for the previous 30 consecutive business days. This notification has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Global Market. In accordance with Nasdaq Listing Rules, the Company has a period of 180 calendar days, or until November 27, 2024, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days during this 180-calendar day period. If at any time during this 180-calendar day period the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide the Company with written confirmation that it has regained compliance with the minimum bid price requirement and this matter will be closed."

16:23 EDT Qiagen sees pre-tax restructuring charge of $ 400M or $1.40 per share - As a result of this decision, and combined with related actions, QIAGEN expects to incur a pre-tax restructuring charge of approximately $400 million or about $1.40 per diluted share after taxes , and predominantly in the second quarter of 2024. This charge, which will be excluded from adjusted results, includes approximately $300 million of non-cash items. These include about $90 million for inventory and about $210 million for long-term assets of which about $120 million for acquired intellectual property . Cash charges involve commitments to customers and suppliers, severance payments and other obligations. Related workforce reductions will be handled in a socially responsible manner with respect for affected employees and in compliance with local labor laws.

16:21 EDT Qiagen sees pre-tax restructuring charge of $ 400M or $1.40 per share - As a result of this decision, and combined with related actions, QIAGEN expects to incur a pre-tax restructuring charge of approximately $400 million or about $1.40 per diluted share after taxes , and predominantly in the second quarter of 2024. This charge, which will be excluded from adjusted results, includes approximately $300 million of non-cash items. These include about $90 million for inventory and about $210 million for long-term assets of which about $120 million for acquired intellectual property . Cash charges involve commitments to customers and suppliers, severance payments and other obligations. Related workforce reductions will be handled in a socially responsible manner with respect for affected employees and in compliance with local labor laws.

16:17 EDT Offerpad Solutions to join Russell 2000 and 3000 indices on July 1st - Offerpad Solutions announced that Offerpad is expected to be included in the Russell 2000(R) and 3000(R) Indexes effective at the open of U.S. equity markets on July 1, 2024.

16:15 EDT C.H. Robinson names Damon Lee CFO - C.H. Robinson Worldwide announced the appointment of Damon Lee as its new Chief Financial Officer, pursuant to the previously announced Chief Financial Officer transition. This strategic hire comes after a comprehensive search for a candidate with a proven track record of successfully leading transformations, recognized operational expertise and demonstrated leadership and strategic capabilities. Lee will commence employment with C.H. Robinson on July 8, 2024, and will assume the role of Chief Financial Officer the day after the Form 10-Q is filed for the 2024 second quarter. To facilitate a seamless transition, Mike Zechmeister will continue to serve as C.H. Robinson's Chief Financial Officer until then, and depart at that time, after which he plans to retire. "We are excited to have Damon join our senior leadership team," said Dave Bozeman, C.H. Robinson's President and Chief Executive Officer. "Damon's extensive experience and expertise align perfectly with the high standards and forward-thinking mindset we prioritize at Robinson. He is a highly accomplished finance leader, and his ability to create and execute a comprehensive strategy is a core strength. Damon's deep experience with Lean and continuous improvement will be a significant benefit in further reinforcing our new operating model and executing our enterprise strategy. He also has built and led high-performing teams, fostered collaboration, and developed personal connections that have enabled him to accelerate change."

16:15 EDT Planet Labs says Tanager-1 ready for launch - Planet Labs announced that its first hyperspectral satellite, Tanager-1-made possible by the Carbon Mapper Coalition and its philanthropic partners-is ready for launch. The spacecraft arrived at Vandenberg Space Force Base on June 3rd in preparation for liftoff as early as July on board the Transporter-11 Rideshare mission with SpaceX. Tanager-1 will be the first of a next-generation hyperspectral fleet which will expand Planet's imaging capabilities in the spectral domain to complement the existing imaging capabilities in the temporal and spatial domains offered by the PlanetScope, SkySat, and Pelican missions. Following on-orbit commissioning, Tanager-1 is planned to provide hyperspectral data both in support of the continued partnership with nonprofit organization Carbon Mapper and Planet's broader commercial mission. Tanager-1 was enabled by the Carbon Mapper satellite program, which allowed Planet to combine its cutting-edge agile aerospace and smallsat bus technology with the state-of-the-art imaging spectrometer design developed at NASA's Jet Propulsion Laboratory. This collaboration plans to provide scientific-grade data to enable action on sustainability use cases such as greenhouse gas point-source emissions. "This important collaboration with Planet and Carbon Mapper is an innovative way to confront Earth's most urgent climate challenges head-on," said Laurie Leshin, Director of NASA JPL. "Our imaging spectrometer technology and expertise, leveraged and deployed on Tanager-1, will enable a broad range of stakeholders to pinpoint methane super-emitters and take action to mitigate them. The work of the Carbon Mapper Coalition will truly have a global impact, and we are proud to take part in ensuring mission success."

16:14 EDT DocuSign reports Q1 adjusted gross margin 82% - Q1 non-GAAP gross margin was 82.0% compared to 82.6% in the same period last year. GAAP gross margin was 78.9% compared to 79.4% in the same period last year.

16:13 EDT Andersons signs LOI to purchase interest in Skyland Grain - Andersons and Skyland Grain have signed a non-binding letter of intent for The Andersons to purchase an ownership interest in Skyland, operating in South Central and Southwest Kansas, Northwest Oklahoma, Eastern Colorado, and Texas. The Andersons has been granted exclusivity while the parties work in good faith to negotiate a definitive agreement. There can be no assurance that the parties will enter into a definitive agreement or that the proposed transaction will be completed.

16:12 EDT Emerson Electric sells remaining interests in Copeland to Blackstone for $3.5B - Emerson (EMR) announced that it has entered into a definitive agreement to sell its remaining interests in the Copeland joint venture for a transaction value of approximately $3.5B, with pre-tax cash proceeds of $3.4B, net of the release of $0.1B of future indemnity obligations. Private equity funds managed by Blackstone (BX) will purchase Emerson's 40% common equity ownership in the joint venture, while Copeland will repurchase the seller's note. The transactions have been unanimously approved by Emerson's Board of Directors and are expected to close in the second half of calendar year 2024, subject to regulatory approvals and customary closing conditions. The transactions are expected to result in a net pretax gain of approximately $0.2B. Emerson intends to use the approximate $2.9B after-tax cash proceeds to pay down its existing debt obligations. A wholly owned subsidiary of the Abu Dhabi Investment Authority and GIC will invest alongside Blackstone as part of the transaction.

16:10 EDT Qiagen to discontinue NeuMoDx 96 and 288 Molecular Systems - Qiagen announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market developent trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems. This decision will allow QIAGEN to refocus resources and efforts on developing and commercializing other innovative solutions within its portfolio, in particular the QIAstat-Dx system for syndromic testing, the QIAcuity portfolio of digital PCR systems and the QIAGEN Digital Insights bioinformatics business. These are complemented by QIAGEN building on proven leadership positions in Sample technologies and the QuantiFERON-TB franchise. "We recognize the valuable role that the NeuMoDx 96 and 288 Molecular Systems have played in many laboratories, especially in the global response to the COVID-19 pandemic. However, the market dynamics have since changed considerably and we do not see a realistic path to developing this system in a value-creating way. We are committed to supporting our NeuMoDx customers throughout this transition," said Thierry Bernard, CEO of QIAGEN. "This decision underscores our unwavering commitment to focus where we can develop profitable leadership positions, and frees up resources to invest in other portfolio areas."

16:09 EDT Zumiez announces $25M share repurchase program - Zumiez approved the repurchase of up to an aggregate of $25M of common stock. The repurchase program is expected to continue through June 30, 2025 unless the time period is extended or shortened by the board.

16:06 EDT Tilly's reports Q1 SSS down 9.4% y/y - Net sales from physical stores were $92.8 million, a decrease of $5.0 million or 5.1%, compared to $97.8 million last year, with a comparable store net sales decrease of 8.6%. Net sales from physical stores represented 80.1% of total net sales this year compared to 79.1% of total net sales last year. The Company ended the first quarter with 246 total stores compared to 248 total stores at the end of the first quarter last year. Net sales from e-com were $23.0 million, a decrease of $2.8 million or 10.8%, compared to $25.8 million last year. E-com net sales represented 19.9% of total net sales this year compared to 20.9% of total net sales last year.

15:55 EDT Tevogen reports TVGN 489 retains activity against FLiRT strains of SARS-CoV-2 - Tevogen announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes, or CTLs, immunotherapy for treatment of COVID-19 in high-risk patients and Long COVID, retains activity against the currently dominant and highly mutated FLiRT strains of SARS-CoV-2 based on a review of this variant's protein sequences. Named FLiRT to reflect amino acid changes occurring in the spike protein, these Omicron subvariants are descendent from JN.1, the previously dominant strain in the U.S. TVGN 489 contains Cytotoxic T lymphocytes that recognize multiple SARS-CoV-2 proteins, or peptides. TVGN 489's peptide targets have been preserved in all previously studied COVID strains. Continuing surveillance by Tevogen Bio of SARS-CoV-2 variants, show that 95% of these CTLs remain active against FLiRT variants, including KP.2, the current dominant strain.

15:01 EDT Fenbo Holdings Ltd trading resumes

14:59 EDT Scilex says FDA approval of Gloperba commercial manufacturing - Scilex announced that it has the FDA approval of commercial manufacturing of Gloperba, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. and will launch in June. Scilex will stock Gloperba in all major wholesalers and pharmacies starting June 10, the company said in a statement. Scilex added that it has a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S.

14:21 EDT Hertz down 8% after report of possible debt sale - Shares of Hertz Global are down about 8% in afternoon trading after Bloomberg reported that the rental-car company's advisers have begun contacting potential investors regarding the potential sale of at least $700M in secured debt as well as a convertible notes offering.

14:04 EDT Boeing reports successful crewed docking with International Space Station - NASA astronauts Barry "Butch" Wilmore and Sunita "Suni" Williams successfully docked Boeing's Starliner spacecraft to the International Space Station (ISS), about 26 hours after launching from Cape Canaveral Space Force Station, Boeing reported. After spending about a week on orbit, Wilmore and Williams will board Starliner and return home, Boeing stated. "It is both amazing and humbling to join the fleet of commercial spacecraft capable of conducting crewed transportation services to and from the space station for NASA. Our teams have done some great work to get us to this point," said Kay Sears, vice president and general manager of Space, Intelligence & Weapon Systems for Boeing Defense, Space & Security.

14:01 EDT Coeptis stock 'heavily undervalued,' CEO Mehalick tells The Fly

13:43 EDT GameStop trading resumes

13:18 EDT Carvana sees sequential increase in adjusted EBITDA in Q2 - Carvana Co. presented today at the William Blair 44th Annual Growth Stock Conference, sharing progress and updates, including: Efficiency-driven growth. Despite continued focus on profitability initiatives and unit economics, Carvana grew retail units by 16% YoY in Q1, driven in part by improvements in conversion and customer experience. Substantial YoY improvements in unit economics. In Q1, non-GAAP GPU increased 42%, non-GAAP SG&A per unit decreased 17%, and Adjusted EBITDA Margin increased 860 bps. The company reiterated its expectation of a sequential increase in its YoY growth rate in retail units and a sequential increase in Adjusted EBITDA in Q2. Carvana's Adjusted EBITDA provides significant financial flexibility that allows the company to de-lever over time. The company previously announced its intention to pay cash interest on 2028 and 2030 Senior Secured Notes for interest payments beginning in 2025. In Q2, Carvana repurchased $250 million, or 24% of 2028 Senior Secured Notes and raised $350M of equity capital through its at-the-market program. Carvana expects these combined actions to lead to ~$55M of interest expense savings in 2026 and $620M less debt outstanding at year-end 2026. Beyond these steps, the company plans to continue to reduce leverage over time.

12:47 EDT Tomi Environmental announces cost reduction efforts to sustain LT growth - TOMI Environmental Solutions announced comprehensive cost reduction initiatives to align the company's cost structure with targeted profitability objectives. The company's operational cash savings initiatives include: Executives will reduce their compensation by 30% of their current cash compensation for the remainder of 2024, thereby reducing the company's cash requirements for salaries and ensuring alignment of interests with shareholders. Termination of select external consulting agreements, with remaining consultants agreeing to reduce their consultant fees. This initiative, along with reductions in other costs, fosters a leaner and more efficient operational model. These cost-reduction measures underscore TOMI's commitment to enhancing financial performance while maintaining investments in critical areas such as product development and sales team expansion. The company anticipates that these initiatives will result in a 30% or approximately $500,000 reduction in cash used in operations by the end of 2024. This proactive action reinforces TOMI's dedication to delivering long-term value to shareholders and achieving profitability, while sustaining innovation and growth momentum in its core business segments. The Company believes it is nearing the close of another CES contract with a prominent cell and gene therapy facility in the United States. The customer is a current user of TOMI mobile equipment, and is currently in phase two of a bid scheduled for a next month close. This contract includes a SteraMist CES, which has already been allocated in the budget for approximately $450,000. The project is currently scheduled for completion by the end of 2024.

12:06 EDT 3D Systems rises 10.3% - 3D Systems is up 10.3%, or 43c to $4.59.

12:03 EDT Smartsheet rises 16.0% - Smartsheet is up 16.0%, or $6.04 to $43.81.

12:01 EDT Dorian LPG falls -11.5% - Dorian LPG is down -11.5%, or -$5.79 to $44.51.

12:00 EDT Sprinklr falls -16.3% - Sprinklr is down -16.3%, or -$1.77 to $9.07.

11:40 EDT Chipotle shareholders approve increase in authorized shares needed for split - Chipotle Mexican Grill announced that during its annual meeting, its shareholders approved an increase in the number of authorized shares of its common stock, which is necessary to facilitate the company's 50-for-1 stock split. "This will be one of the biggest stock splits in New York Stock Exchange history," stated the company, which notes that shareholders of record as of June 18 will receive 49 additional shares for each share held, which will be distributed after market close on June 25. Chipotle's shares will begin trading on a post-split basis at the market open on Wednesday, June 26. "We believe the stock split will make our stock more accessible to our employees as well as a broader range of investors. With this historic decision, we'll be better able to reward our team members and empower them to have ownership in our company," said Jack Hartung, Chief Financial and Administrative Officer, Chipotle.

11:26 EDT Barinthus presents EOT data from Phase 2a trial of imdusiran, VTP-300 - Data from IM-PROVE II as of the data cutoff on April 12, 2024, indicate that treatment with imdusiran, Arbutus' RNAi therapeutic candidate, followed by Barinthus Bio's T-cell stimulating immunotherapeutic candidate, VTP-300, was generally well-tolerated and observed to maintain low HBsAg levels during the post-treatment follow-up period. The data were presented today by Dr. Kosh Agarwal, MD, Consultant Hepatologist and Transplant Physician at the Institute of Liver Studies at King's College Hospital, London, during a session focused on new treatments for viral hepatitis B at the EASL Congress. Dr. Agarwal presented the following data from 38 of 40 participants that were on stable NUC therapy throughout the treatment period. They received imdusiran for 24 weeks and were then randomized to receive either VTP-300 or placebo at Weeks 26 and 30: Robust reductions of HBsAg were observed during the imdusiran lead-in period with 95% of patients achieving HBsAg less than100 IU/mL before undergoing dosing in the VTP-300 treatment or placebo groups. At 24-weeks post-EOT, there was a significant difference in HBsAg levels between the VTP-300 treatment group and placebo. 94% of participants in the VTP-300 treatment group achieved HBsAg levels of less than100 IU/mL and 36% had less than10 IU/mL at EOT compared to the placebo group, 84% and 21%, respectively. Similarly, at 24-weeks post-EOT, the VTP-300 treatment group had lower HBsAg levels with 80% of participants at less than100 IU/mL and 60% at less than10 IU/mL than the placebo group, 16% and 0%, respectively. 84% of participants in the VTP-300 treatment group met criteria at EOT to discontinue NUC therapy vs 52% in the placebo group. In the VTP-300 treatment group, 20% of participants achieved undetectable HBsAg at 24-weeks post-EOT and a further 20% of participants had a greater than1.5log10 decline between the last two visits during the NUC therapy discontinuation follow-up period. Treatment with imdusiran and VTP-300 was generally well-tolerated. There were no reported SAEs, Grade 3 or 4 AEs or discontinuations due to treatment. The most common treatment-related AEs in two or more patients were injection site-related and transient ALT increases.

11:19 EDT Arbutus announces preliminary EOT data from Phase 2a trial of imdusiran, VTP-300 - Arbutus Biopharma Corporation (ABUS) announced new preliminary end-of-treatment data from the Phase 2a clinical trialin patients receiving ongoing standard-of-care nucleos(t)ide analogue therapy indicating that treatment with imdusiran, Arbutus' RNAi therapeutic, followed by Barinthus Biotherapeutic's (BRNS) T-cell stimulating immunotherapeutic, VTP-300, was generally safe, well-tolerated and led to maintenance of lower HBsAg levels during the post-treatment follow-up period in patients with cHBV. The data were presented today by Dr. Kosh Agarwal, MD, Consultant Hepatologist and Transplant Physician at the Institute of Liver Studies at King's College Hospital, London, during a session focused on new treatments for viral hepatitis B at the European Association for the Study of the Liver Congress. Dr. Agarwal presented the following data from 38 of 40 patients that were on stable NA therapy throughout the treatment period, received imdusiran for 24 weeks and were then randomized to receive either VTP-300 or placebo at Weeks 26 and 30: Robust reductions of HBsAg were seen during the imdusiran lead-in period with 95% of patients achieving HBsAg less than100 IU/mL before undergoing dosing in the treatment or placebo arm. At 24-weeks post-EOT, there was a significant difference in HBsAg levels between the treatment arm and placebo. 94% of patients in the treatment arm achieved HBsAg levels of less than100 IU/mL and 36% had less than10 IU/mL at EOT compared to 84% and 21%, respectively in the placebo arm. Similarly, at 24-weeks post-EOT, the treatment arm had lower HBsAg levels with 80% of patients at less than100 IU/mL and 60% at less than10 IU/mL compared to the placebo arm with 16% and 0%, respectively. 84% of patients in the treatment arm met the NA therapy discontinuation criteria and stopped NA treatment after Week 48 compared to 53% in the placebo arm. One patient in the treatment arm achieved undetectable HBsAg and another had a greater than1.5 log10 decline between the last two visits during the NA-therapy discontinuation follow-up period. Treatment with imdusiran and VTP-300 was generally safe and well-tolerated. There were no Serious Adverse Events, Grade 3 or 4 Adverse Events or discontinuations due to treatment. The most common treatment-related AEs in two or more patients were injection site-related and transient ALT increases.

11:09 EDT Digital Health Acquisition Corp trading resumes

11:01 EDT Tonix Pharmaceuticals announces 1-for-32 reverse stock split - Tonix Pharmaceuticals Holding Corp. announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock. The reverse stock split will be effective for trading purposes as of the commencement of trading on June 10, 2024. The reverse stock split is intended to increase the per share trading price of Tonix's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market.

11:00 EDT FDA rescinds ban on Juul Labs e-cigarettes - The FDA is providing an update on the status of the agency's review of the premarket tobacco product applications, or PMTAs, submitted by JUUL Labs, noting that on June 23, 2022, the FDA issued marketing denial orders, or MDOs, to JUUL Labs, Inc. for all of their products marketed in the United States at the time. "Today, the FDA rescinded the MDOs issued in June 2022 to JUUL Labs, Inc. This action is being taken, in part, as a result of the new case law, as well as the FDA's review of information provided by the applicant. Rescission of the MDOs is not an authorization or a denial and does not indicate whether the applications are likely to be authorized or denied. Rescission of the MDOs returns the applications to pending status, under substantive review by the FDA. The FDA's regulations significantly limit what the agency can disclose regarding the content of pending applications... The agency's continued review does not alter the fact that all e-cigarette products, including those made by JUUL, are required by law to have FDA authorization to be legally marketed," the FDA stated. Publicly traded companies in the tobacco products space include Altria Group (MO), British American Tobacco (BTI), Imperial Brands (IMBBY) and Philip Morris (PM). Reference Link

10:57 EDT Freshworks completes acquisition of Device42 - Freshworks announced the completion of its acquisition of Device42, a company that provides comprehensive, continuously up-to-date views of assets across an organization's entire IT infrastructure. The acquisition marks a significant milestone for Freshworks, reinforcing its commitment to empowering IT teams with robust IT Asset Management solutions. Upon the integration of Freshworks and Device42 solutions, customers will be able to benefit from a unified platform that delivers enhanced ITSM and ITAM capabilities including advanced asset discovery and application dependency mapping, enabling them to anticipate risks better and resolve incidents faster.

10:22 EDT Plutonian Acquisition Corp trading resumes

10:10 EDT MAIA reports THIO-101 data from third-line treatment shows ORR of 38% - MAIA Biotechnology announced company highlights and key achievements year-to-date, including recent clinical progress for lead candidate THIO, a potential first-in-class cancer telomere targeting agent in clinical development to evaluate its activity in non-small cell lung cancer. THIO's dual mechanism of action is designed to induce telomeric DNA damage and boost cancer-specific immune responses. The Phase 2 THIO-101 clinical trial evaluates THIO sequenced with an immune checkpoint inhibitor cemiplimab, in patients with advanced non-small cell lung cancer who failed two or more standard-of-care therapy regimens prior to THIO dosing. MAIA successfully secured a high value clinical supply agreement for the cemiplimab used throughout the THIO-101 trial. As of April 30, 2024, THIO-101 data from THIO 180mg + CPI in third-line treatment showed, in part: overall response rate of 38%; disease control rate of 85%; median progression-free survival of 5.5 months; median survival follow-up time of 9.1 months. MAIA reported cash and current assets of $8.7M as of March 31, 2024. MAIA's Phase 2 THIO-101 clinical trial is expected to near completion in 2024. The company is also engaged in research and development for a portfolio of second-generation THIO-like compounds.

10:04 EDT Kuke Music rises 11.5% - Kuke Music is up 11.5%, or 33c to $3.20.

10:01 EDT Dorian LPG falls -10.2% - Dorian LPG is down -10.2%, or -$5.12 to $45.18.

10:01 EDT ZIM Integrated falls -11.6% - ZIM Integrated is down -11.6%, or -$2.77 to $21.03.

09:54 EDT Dorian LPG falls -9.4% - Dorian LPG is down -9.4%, or -$4.74 to $45.56.

09:52 EDT Sprinklr falls -16.2% - Sprinklr is down -16.2%, or -$1.76 to $9.08.

09:48 EDT Kuke Music rises 11.1% - Kuke Music is up 11.1%, or 32c to $3.19.

09:44 EDT Knightscope announces City of Phenix, AL signs contract for six K1 Hemispheres - Knightscope announces a new contract for a half dozen K1 Hemisphere Autonomous Security Robots going to the City of Phenix, Alabama. Additionally, a property owner in Nashville, Tennessee, has renewed its contract for their K5 ASR that has been patrolling a parking structure for the past two years.

09:40 EDT Instacart announces new share repurchase program up to $500M - Instacart disclosed that is board approved a share repurchase program with authorization to purchase up to an aggregate of $500M of the company's common stock. At the time of the authorization on June 2, no capacity remained under the $1B share repurchase program previously authorized by the board in November 2023 and February 2024, which program resulted in the repurchase of approximately 34M shares, the company noted. The share repurchase program has no expiration date.

09:36 EDT Ryde Group Ltd trading halted, volatility trading pause

09:32 EDT Mobile-health Network Solutions announces update to AI-powered MHOS - Mobile-health Network Solutions announces the latest major update to its cloud-based MaNaDr AI-Powered Health Operating System designed to transform healthcare delivery on a global scale. The latest MHOS boasts a suite of powerful features that empower clinics to significantly improve efficiency and patient care. Its key strengths include: Superior Performance: Reduced registration times, streamlined electronic health record system for primary care with functionality to support the day-to-day operations for both virtual and brick-and-mortar practices. MHOS includes features such as customizable medical template, prescription and diagnosis module, care plans, as well as electronic referrals to tertiary centers. Seamless Integration: Fully compliant with Singapore's National Electronic Health Record standards, ensuring secure data exchange and a holistic view of patient history for continuity of care. MNDR prioritizes data privacy and security, and MHOS adheres to the highest industry standards to safeguard sensitive patient information.

09:30 EDT Logistic Properties of The Americas trading halted, volatility trading pause

09:26 EDT Vanda Pharmaceuticals receives indication of interest for $8.00 per share - Vanda Pharmaceuticals has received an unsolicited, non-binding indication of interest from Cycle Group to acquire the company for $8.00 per share in cash. The Vanda Board of Directors will review and evaluate the indication of interest to determine the course of action that the Board believes is in the best interests of Vanda and its shareholders. There is no action for shareholders to take at this time.

09:18 EDT Kuke Music entering AI music field - Kuke Music announced the formation of a professional AI team for development and operations, as well as a marketing team, to enter the AI music field. AI-enhanced music will be launched on Kuke's app and on various automotive in-car networking platforms. Kuke will leverage AI technology to provide intelligent music recommendations, automatically generate music content, and offer personalized services to enhance user experience. The company plans to continue investing in AI music research and development.

09:15 EDT Nextech3D.AI announces advancement in AI-powered photography technology - Nextech3D.AI announces a significant advancement in its AI-powered photography technology: the ability to create dynamic lifestyle images from 3D models or CAD files, representing a significant leap from 2D photography to 3D renders and photos. AI is transforming the virtual photography landscape for ecommerce, as the company is producing tens of thousands of 3D models annually it expects to produce hundreds of thousands of 3D model renders to its same customer base and expand with new customers. The company believes that its AI Photography with Advanced Lifestyle Image Creation is a large opportunity for revenue growth.

09:10 EDT Sprout Social announces AI innovations, 20 new product capabilities - Sprout Social announced a series of AI-powered product enhancements alongside 20 new capabilities across its platform to help marketers prioritize what matters most, enhance creativity and drive more business impact with social. Many of these will be featured in Breaking Ground, Sprout's new quarterly showcase of the company's latest product innovations. With heightened expectations for quick and personalized customer connections across social, brands are at capacity and often struggle to prioritize impactful and creative work. Sprout's latest product innovations will help solve these common challenges by automating key elements of content creation, reporting and social care. Standout AI capabilities include Generate by AI Assist, which makes it easier for brands to improve accessibility by writing highly accurate alt-text for images, and Analyze by AI Assist, which surfaces notable performance and conversation trends for brands. Sprout's new AI solutions also classify and prioritize inbound messages, replace manual data analysis and craft suggested responses. This human-centered approach to AI saves businesses valuable time, provides better access to actionable data and allows teams to focus on more strategic and creative thinking.

09:08 EDT Backblaze launches Blackblaze B2 Live Read offering - Backblaze announced the launch of Backblaze B2 Live Read. The offering gives customers, particularly media production teams working on live events, the ability to access, edit, and transform content while it is still being uploaded into B2 Cloud Storage, resulting in significantly faster and more efficient workflows. This patent-pending innovation is a brand new type of service in cloud workflows, replacing cost prohibitive and complicated options that often required on-premises storage. Leading media and entertainment production solution providers including Telestream, Glookast, and Mimir have already committed to integrating the service.

09:07 EDT Edible Garden Pulp products available at a major big box retailer's locations - Edible Garden announced that its Pulp sustainable and fermented products, are now available at a major big box retailer's locations across the Midwest. Jim Kras, Chief Executive Officer of Edible Garden, stated, "We are extremely pleased that, after a successful initial soft launch at new store openings, our unique range of Pulp fermented products is now available across the big box retailer's locations in the Midwest. We believe this expansion is a significant validation of the strong customer and retail appeal of the products due to their distinctive flavors and ability to enhance taste. As one of our most significant and long-standing partners, this retailer has been instrumental in helping Edible Garden reach a broader audience. This broad rollout not only increases the reach of our innovative products across the Midwest, but also strengthens our position as 'The Flavor Maker' within the food industry."

09:06 EDT Tiziana Life Sciences announces results for na-SPMS patients enrolled in EAP - Tiziana Life Sciences announced the qualitative results for all 10 non-active Secondary Progressive Multiple Sclerosis, na-SPMS, patients enrolled in the intermediate-size patient population Expanded Access Program, EAP, receiving foralumab for at least six months. Gabriele Cerrone, Chairman, acting CEO, and founder of Tiziana Life Sciences, added, "I am thrilled that 80% of the na-SPMS patients who received intranasal foralumab treatment for at least 6-months have a qualitative reduction of microglial activity as confirmed in these latest PET images. I am also greatly appreciative of Dr. Singhal's research and look forward to the additional quantitative analysis of the data. With the allowance of an additional 20 patients in the EA program, the application for Orphan Drug Designation for na-SPMS, and the ongoing Phase 2a trial, Tiziana is rapidly progressing its intranasal foralumab program in multiple sclerosis."

09:05 EDT Syla Technologies completes construction of SYLA TOYOCHO office building - SYLA Co. has announced the planning and completion of its first office building in Toyo 3-chome, Koto-ku, Tokyo. SYLA's inaugural office building is designed with a concept that emphasizes the sharp, harmonious integration of materials, blending seamlessly with the cityscape. The design leverages the horizontal lines of the floor, utilizing simple materials such as autoclaved lightweight concrete panels and glass. This approach emphasizes unity with the urban environment. At the building's entrance, a gate facing the street enhances both convenience and aesthetic harmony with the city.

09:03 EDT Udemy launches new generative AI upskilling program with Amazon Web Services - Udemy (UDMY) announced the launch of a new generative artificial intelligence, or AI, upskilling program developed in collaboration with Amazon (AMZN) Web Services, or AWS. Offered through Udemy Business Leadership Academy, or UBLA, Unlocking GenAI Opportunities with AWS is a six-week cohort learning program designed to equip leaders across all industries with the generative AI tools and change management strategies they need to successfully develop talent and drive the digital transformation within their organization.

09:02 EDT Sintx Technologies receives additional SBIR contract for 3D printing technology - SINTX Technologies announced that its wholly-owned subsidiary, Technology Assessment and Transfer has been selected by AFWERX for a 3-month, $75,000, phase I Small Business Innovation Research, SBIR, contract focused on Enhanced Sinterability of Complex-Shaped 3D Printed Silicon Nitride, Si3N4. This contract will address material challenges in propulsion and guidance technology for next generation high-temperature Department of the Air Force systems. The Air Force Research Laboratory, AFRL, and AFWERX have partnered to streamline the SBIR and STTR process by accelerating the small business experience. The DAF began offering the Open Topic SBIR/STTR program in 2018, and now, through this partnership, TA&T will expand its ability to create and provide innovative capabilities that will strengthen the defense of the United States of America. If successful, TA&T/SINTX will attempt to leverage this work into an AFWERX phase II contract worth up to $1.25M over 21 months.

09:01 EDT Starbucks, Grubhub launch delivery partnership - Starbucks and Grubhub announced a partnership to bring Grubhub delivery to Starbucks customers in the U.S. Starbucks is the most searched merchant not yet available on Grubhub's Marketplace, and through this partnership, both brands will provide customers with the ultimate convenience of having their Starbucks orders delivered right to their door. Beginning in June, Starbucks Delivery with Grubhub will roll out to select markets in Pennsylvania, Colorado and Illinois, with national availability anticipated in all 50 states across the U.S. by August 2024.

08:59 EDT Colorado awards data management deal to Conduent, no terms - Conduent announced the company has been selected by the Colorado Department of Health Care Policy and Financing to provide Business Intelligence and Data Management BIDM) technology services. Under terms of the new contract, Conduent will take over, manage and enhance a modular enterprise data warehouse solution to support advanced data analysis and reporting capabilities as part of the state's Medicaid Enterprise System, MES.

08:54 EDT Lyft provides 2027 targets at first investor day - Lyft will host its first Investor Day. The event will feature presentations by Lyft's CEO David Risher, CFO Erin Brewer, and other leaders from across the company, who will discuss Lyft's plans. The event will conclude with a live Q&A session. By 2027 the company expects: a Gross Bookings compound annual growth rate of approximately 15% between full-year 2024 and full-year 2027; an Adjusted EBITDA margin of approximately 4% on a full-year basis in 2027 and free cash flow conversion of more than 90% annually each year between 2025 and 2027.

08:47 EDT AbbVie's mirvetuximab soravtansine meets Phase 2 efficacy endpoint - AbbVie announced positive topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine monotherapy in heavily pre-treated patients with folate receptor-alpha positive, platinum-sensitive ovarian cancer. The study met its primary endpoint with an objective response rate - ORR - of 51.9%. In addition, the median duration of response, a key secondary endpoint, was 8.25 months. The safety profile of mirvetuximab soravtansine was consistent with findings from previous studies, and no new safety concerns were identified. Full data from the PICCOLO study will be presented at a future medical meeting. Mirvetuximab soravtansine is also being studied in PSOC in the Phase 3 GLORIOSA trial, in combination with bevacizumab versus bevacizumab alone in maintenance after second-line platinum-doublet therapy.

08:38 EDT Visionary Holdings signs tokenization partnership with ABB-FG - Visionary Holdings and ABB-FG - American Business Brokerage & Funding Grp - from the U.S., signed a Tokenization Partnership Agreement. The parties wish to form a Partnership to develop the business of tokenization and securitization of Real-World Assets in Canada. ABB-FG will register various real-world assets with the SEC. These assets will be supported by public blockchain and token platforms and will be listed for uninterrupted trading on major global digital asset exchanges. After digitizing and securitizing the properties at 95-105 Moatfield Dr, ABB-FG will facilitate their global trading on ATS.

08:38 EDT Safety Shot announces partnership with Capital Drugs - Safety Shot announced its partnership with Capital Drugs as the brand expands its nationwide availability. Making strides in connecting the brand to its overarching wellness purpose, Safety Shot will be available in all 300 of the drugstore chain's pharmacies across the United States. "Entering Capital Drugs pharmacies is an integral next step in furthering Safety Shots key messaging and purpose of operating as a functional wellness beverage" said Josh Wagner, Chief Revenue Officer at Safety Shot. "Expanding on-shelf availability and having the product available for purchase in key locations like Capital Drug pharmacies is the brand's core mission, introducing the first-of-its-kind beverage to a like-minded consumer audience."

08:37 EDT Mangoceuticals receives Notice of Acceptance for patent application in Australia - Mangoceuticals announces that it has received a Notice of Acceptance for Australian Patent Application No. 2020235666, which is the National Phase of International Application No. PCT/US2020/022903. Following the Company's recent receipt of a Notice of Allowance from Japan, this additional patent acceptance from Australia forges a significant milestone following MangoRx's recent acquisition of the comprehensive global patent portfolio from Intramont Technologies on April 24, 2024. Jacob Cohen, Co-Founder and CEO of MangoRx commented, "Receiving this Notice of Acceptance in Australia is yet another critical step in our strategy to protect and commercialize our innovative preventive care technology on a global basis. It further underscores our commitment to expanding our reach and providing advanced preventive care solutions to a broader audience. This patent not only fortifies our intellectual property but also paves the way for introducing our cutting-edge products to the Australian market."

08:36 EDT CorMedix announces CMS grants pass-through status to DefenCath - CorMedix announced that the Center for Medicare & Medicaid Services, CMS, has determined that DefenCath qualifies for pass-through status under the hospital Out-Patient Prospective Payment System, OPPS. Pass-through status provides for separate payment under Medicare Part B for the utilization of DefenCath in the out-patient ambulatory setting for a period of at least two years, and up to a maximum of three years.

08:35 EDT Nature's Miracle named authorized distributor and seller of OSRAM luminaires - Nature's Miracle has signed a strategic agreement with Traxon Technologies to distribute OSRAM general lighting luminaires for horticulture lighting applications in the U.S. Traxon Technologies, together with its control brand, e:cue, provides solid state lighting and control systems providing complete, sustainable and intelligent lighting solutions. Prior to December 2022, Traxon was the LED lighting division under ams OSRAM, a global light and sensor solution provider with more than 100 years of industry experience and Traxon is now a licensee of Osram general lighting products. With this agreement, Nature's Miracle will be the exclusive authorized distributor and seller of OSRAM General Lighting Luminaires for horticulture applications in the U.S. Nature's Miracle expects sales of this new line to begin in Q3. Under the Agreement, minimum sales are expected to be reach at least $8M in 2026.

08:35 EDT Bridgeline Digital announces release date of HawkSearch 'Athena' update - Bridgeline Digital announced the release date of its HawkSearch "Athena" update, which is set for June 13, 2024. The Athena release introduces new GenAI capabilities with "Smart Responses," transforming customer interactions with search, leading to increased engagement and revenue for businesses. HawkSearch will introduce its "Athena" update with GenAI-powered "Smart Responses" to increase conversions for eCommerce customers. The Smart Response features engage users with interactive conversational dialogue based on search queries. It prompts follow-up questions and suggestions, imitating a personalized online sales assistant. This enhances engagement and ensures users find what they need efficiently. For example, when a user types "solar panels" on a solar panel eCommerce site, HawkSearch Smart Response will display detailed installation instructions and summarize the types of solar panels available, as well as their best uses. This empowers users to make more informed and confident purchasing decisions.

08:34 EDT SurgePays announces launch of prepaid wireless brand LinkUp Mobile - SurgePays announced that they have launched the LinkUp Mobile website and are well underway in the national rollout. CEO Brian Cox stated, "We are excited to deliver this service to the expanding robust prepaid market in North America. We aim to revolutionize the industry with our unique subscription model. Subscribers enjoy a free first month of service and ongoing savings of up to 10% each month, setting us apart from the competition. Our goal was to create operational and economic efficiencies to enable us to offer a free month of service and ongoing savings to the consumer for their loyalty. We believe a huge opportunity exists to enhance the prepaid customer experience and utilize each new subscriber as a potential multiproduct consumer by offering more value to an often-overlooked market."

08:33 EDT Ipsen appoints Josep Catla as EVP, chief corporate affairs officer - Ipsen (IPSEY) announced the appointment of Josep Catlla as EVP, Chief Corporate Affairs Officer, effective August 19, 2024. He will serve on the Executive Leadership Team and report directly to Ipsen's CEO David Loew. Josep joins Ipsen from Sanofi (SNY), where he has spent the last 14 years in leadership positions at country, region and corporate levels.

08:33 EDT Dolby to acquire GE Licensing from GE Aerospace for $429M in cash - Dolby Laboratories announced that it has entered into a definitive agreement to acquire GE Licensing, which owns, maintains, and licenses an extensive portfolio of IP primarily targeting the consumer digital media and electronics sectors. Dolby Laboratories has agreed to acquire GE Licensing, an intellectual property licensing business primarily targeting the consumer digital media and electronics sectors, in a $429M all cash transaction. This deal is expected to close by the end of fiscal year 2024, subject to regulatory approval and other customary closing conditions, and is not expected to have a material impact on Dolby's fiscal year 2024 results. This transaction includes attractive complementary assets that strengthen and expand Dolby's patent portfolios, and represents a compelling financial profile of durable, high-margin revenue. Dolby expects the deal to be accretive on a non GAAP basis to operating margins and EPS in fiscal 2025. This transaction is not expected to affect Dolby's practice of returning capital to stockholders through its quarterly dividend and through stock repurchases to offset dilution from stock-based compensation.

08:31 EDT Iris Energy mines 230 bitcoin in May - IREN published a monthly investor update for May 2024. May operations Average operating hashrate of 9.4 EH/s; now expanded to 10 EH/s; Decrease in Bitcoin mined in May due to reduced block subsidy, partially offset by 14% increase in average operating hashrate. 2024 expansion plans increased to 30 EH/s: Secured latest-generation Bitmain S21 Pro miners with nameplate efficiency of 15 J/TH; At 30 EH/s, nameplate fleet efficiency of 16 J/TH and indicative electricity cost per BTC of $17k; Upgrade of existing miner fleet across BC and Texas; Miners secured to support 40 EH/s in 1H 2025.

08:31 EDT WNS teams with Brightview on digital procurement transformation project - WNS Limited announced its partnership with Brightview Senior Living. WNS has been selected as the preferred design, implementation and integration partner for Brightview's comprehensive digital procurement transformation project. "Brightview's selection of WNS Procurement for this transformative project will help drive tangible enhancements including both operational efficiency and procurement effectiveness. WNS Procurement will implement Ivalua's leading spend management platform, focusing on delivering sustainable, digitally-led business improvements and bottom-line results for Brightview," said Keshav R. Murugesh, Group CEO, WNS. "

08:29 EDT Ensysce Biosciences selects PF9001 to move into IND-enabling studies - Ensysce Biosciences announced the achievement of a critical milestone in its opioid use disorder program with the selection of a lead drug candidate to move into Investigational New Drug enabling studies. Designed with the application of Ensysce's TAAP platform to reduce the abuse profile, lead candidate PF9001 has shown lower potential for cardiovascular side effects associated with traditional methadone opioid use disorder treatments. This work has been supported by a multi-year Helping to End Addiction Long-Term award of up to $15 million granted by the NIH and National Institute on Drug Abuse.

08:20 EDT Healwell AI, Takeda partner to support rare disease RWE analysis - HEALWELL AI (HWAIF) announced its subsidiary Pentavere Research Group has engaged in a partnership and commercial engagement with Takeda Canada (TAK) to drive real-world evidence analysis for rare diseases, particularly focusing on supporting patients suffering from hereditary angioedema with normal C1 inhibitor across Canada. HAE with normal C1 inhibitor is an ultra-rare disease characterized by life-threatening recurrent, unpredictable swelling, and currently does not have any approved treatments. The scarcity of real-world data on the prevalence and clinical outcomes of these patients poses a significant challenge to the development of novel therapeutic agents. Recognizing this critical unmet need, Takeda has collaborated with Pentavere and top HAE specialists across Canada to support research into the gaps in treatment guidelines and approved therapies for these patients. This innovative research collaboration has resulted in the generation of one of the largest cohort datasets globally of hereditary angioedema with normal C1 inhibitor patients. The comprehensive dataset compiled through this partnership will play a pivotal role in filling the real-world data gap on the burden of disease and clinical outcomes for HAE with normal C1 inhibitor patients. By leveraging advanced data science techniques, Pentavere analyzed this dataset as part of the PROSPECT study to extract actionable insights that can inform treatment strategies and improve patient outcomes. A manuscript and an abstract on the PROSPECT study data are currently under preparation and will be submitted for publication soon.

08:18 EDT A2Z Smart Technologies streamlines corporate structure - In a strategic move to focus on its Smart Carts/Cust2Mate business, A2Z has streamlined its corporate structure. Mr. Gadi Graus has been appointed as the CEO of both A2Z and Cust2Mate. Under his leadership, the Company aims to scale operations across all facets, including sales, delivery and manufacturing, while pursuing larger deals and ensuring that investments enhance shareholder value. Additionally, the Board of Directors has been expanded with the appointment of Mr. Reeves D. Ambrecht as a director supporting global expansion through further strategic, corporate development, and capital endeavors. A2Z successfully raised an aggregate of $5,700,000 through the issuance of both restricted stock and unrestricted stock. Certain directors and officers of the Company participated in the registered direct offering and the private placement, contributing $525,000. The net proceeds from this capital raise will be used primarily for the continued development and expansion of A2Z's existing business, including the fulfillment of contracted smart cart backlog orders, acceleration of the onboarding process for new clients and working capital purposes.

08:17 EDT Core Scientific rejects unsolicited proposal from CoreWeave - Core Scientific confirmed that it received an unsolicited non-binding proposal from CoreWeave on June 3 to acquire all of the outstanding shares of the company on a fully diluted basis for $5.75 per share in cash. This unsolicited proposal immediately followed Core Scientific and CoreWeave entering into a series of 12-year contracts for Core Scientific to provide approximately 200 MW of infrastructure to host CoreWeave's high-performance compute services. The company's board of directors, in consultation with its independent financial and legal advisors, carefully reviewed the proposal. The board has evaluated the company's growth prospects and near- and long-term value creation potential, including in connection with both the previously announced CoreWeave agreements and the proposal. The board determined that the CoreWeave proposal significantly undervalues the Company and is not in the best interests of the company and its shareholders.

08:15 EDT A2Z Smart Technologies announces Cart 3.0 ready for deployment - A2Z Smart Technologies provided an update on recent corporate developments and product readiness, including deployment plans for its flagship product, the Cust2Mate smart cart. Gadi Graus, CEO of A2Z, commented, "We are thrilled with the progress we have made in refining our corporate structure, advancing our product capabilities and positioning Cust2Mate as a leading solution in the smart retail space. These developments reflect our commitment to innovation, operational excellence and enhancing shareholder value. We look forward to accelerating our growth trajectory and bringing our revolutionary smart cart solutions to more markets around the world." A2Z announced that Cart 3.0 is ready for deployment. This new version features a detachable control panel, overhauled software for seamless transition from 2.5 to 3.0 carts, reduced costs and weight of control panels, integration with a new generation security scale and continuous software improvement further enhancing the customer experience. The control panel kits are designed for a four-minute retrofit on existing carts, and the check-in and check-out units are ready to be installed. The initial deployment of Cust2Mate 3.0 carts will commence across at least three chains on three continents, including Yochananof in Israel, Morton Williams in New York and Monoprix in France. Additionally, Cust2Mate 3.0 carts have been shipped to local partners in France, Romania, Central America, Thailand and Australia in anticipation of further deployments. A2Z continues to enhance its theft mitigation solutions and infrastructure, introducing new measures for anomaly detection and corresponding actions based on identified anomalies. The Company is developing AI-driven tools to improve weight discrepancy detection and reduce noise. These advancements enable A2Z and its clients to make informed product decisions, balancing theft mitigation with a frictionless user experience. Additionally, a generic POS gateway has been developed to streamline integration with new partners and customers.

08:14 EDT B2Gold announces support of Glass Lewis, ISS recommend shareholders vote 'FOR' - B2Gold announces the support of Glass Lewis & Co. and Institutional Shareholder Services, ISS, who have recommended that shareholders vote FOR all proposed items to be considered at the upcoming Annual General and Special Meeting of Shareholders to be held on Thursday, June 20, 2024. At the Meeting, shareholders are being asked to vote on four items: Election of the directors; Appointment of the Auditor; Approval of unallocated options under the Company's stock option plan; and A non-binding, advisory vote on the Company's approach to executive compensation. The Board of Directors recommends shareholders vote FOR on all four items.

08:11 EDT Tonix Pharmaceuticals announces oral presentations involving TNX-1500 - Tonix Pharmaceuticals announces two oral presentations and a poster presentation at the American Transplant Congress 2024, held June 1-5, 2024 at the Pennsylvania Convention Center, Philadelphia, Pa. "We remain encouraged by the potential of our TNX-1500, Fc-modified humanized anti-CD40L monoclonal antibody therapy for the prevention of rejection in solid organ transplantation," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "Despite advancements in the field of solid organ transplantation, there remains a significant need for new treatments with improved activity and tolerability. Several lines of research indicate that anti-CD40L therapy may improve outcomes for allograft acceptance, and that anti-CD40L therapy may be required for long term xenograft acceptance. We are excited about the broad potential of TNX-1500, on the prevention of allograft and xenograft rejection and also for the treatment of autoimmune diseases like systemic lupus erythematosus and Sjogren's Syndrome."

08:10 EDT American Oncology Network expands radiation oncology services - American Oncology Network announced the expansion of its radiation oncology services with the opening of Low Country Radiation in Waycross, Georgia. Under AON's leadership and with access to the network's array of resources and support, Low Country Radiation will further improve its radiation therapy services with no disruption to patient care. Current patients will continue to receive care from their trusted physicians at the same location, and the practice will remain a participant in patients' insurance networks. "AON's mission has always been to make high-quality cancer care and services accessible to all," said Todd Schonherz, AON's chief executive officer. "The opening of Low Country Radiation expands our reach and ensures patients have access to the latest radiation therapy and compassionate support. This commitment to the practice and patients is a testament to the power of a shared purpose and mission toward improving cancer care for years to come."

08:09 EDT TRM Labs in process of FedRAMP compliance through partnership with Palantir - TRM Labs announced it is in the process of achieving Federal Risk and Authorization Management Program, FedRAMP, and Impact Level, IL, 4 and 5 compliance through a partnership with Palantir Technologies' FedStart Program. This status marks a critical milestone in TRM's journey towards achieving full FedRAMP High Authorization, or Authority to Operate, ATO, and underscores the company's commitment to meeting stringent federal security and compliance standards. TRM has partnered with Palantir, using its FedRAMP-authorized Palantir Federal Cloud Service environment to facilitate and expedite the certification process. TRM is currently undergoing a Significant Change Request process to be added to Palantir's existing accreditation package, which will authorize the TRM Blockchain Intelligence Platform initially at the FedRAMP Moderate impact level, and lay the groundwork to achieve FedRAMP High impact later this year.

08:08 EDT Sprinklr, Reddit expand strategic partnership - Sprinklr (CXM) and Reddit (RDDT) announced an expanded strategic partnership. The partnership spans both Reddit's Data API as well as its Advertising API, which is now open with Sprinklr as the first official partner. Sprinklr works with many of the largest brands in the world to bring together teams, tools, and data for every customer facing team on one unified platform. Deep partnerships with social and digital channels help Sprinklr customers monitor and understand brand-relevant conversations, optimize brand content for maximum reach and engagement, and tailor advertising for maximum effectiveness and ROI. The Reddit Data API provides Sprinklr customers direct access to near real-time public conversations on Reddit. This social listening partnership will show relevant Reddit posts and comments in Sprinklr's interactive customer dashboard. By combining Sprinklr's best-in-class analytics with Reddit's unmatched archive of constantly-updated human conversation, brands and businesses now have access to enhanced feedback and sentiment, trends, and competitive insights to better understand their customers, brand reputation, and power business growth. As Reddit's first advertising API partner, Sprinklr customers can access the full Reddit advertising suite and easily integrate Reddit into their enterprise advertising strategies and campaigns. Enhanced data and insights via the Sprinklr Data API integration can also help inform advertising strategies to reach intended audiences on Reddit.

08:07 EDT Gaia announces availability of 'Love over Money' documentary - Gaia announced the global premiere of its newest feature-length documentary, Love Over Money. The documentary, produced by Joaquin Phoenix and Food Matters, will be available for early access exclusively on Gaia.com beginning today, Thursday, June 6 at 8:00 a.m. MT.

08:06 EDT GSK acquired Elsie Biotechnologies for up to $50M - GSK plc announced that that it has acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for up to $50M, or approximately GBP 39M. This agreement is not subject to closing conditions and the acquisition has been completed. "This acquisition allows GSK to integrate Elsie's oligonucleotide discovery, synthesis, and delivery technologies to enhance GSK's platform R&D capabilities. This follows a successful research collaboration with Elsie, announced in July 2023, in which GSK was able to explore and validate the technology. Data generated with the Elsie platform, combined with GSK's expertise in the use of artificial intelligence and machine learning, will support the development of predictive models for future oligonucleotide design," GSK stated. Tony Wood, Chief Scientific Officer, GSK, said: "We have already made great strides in oligonucleotide drug development through our work in chronic hepatitis B and steatotic liver disease, and are thrilled to work alongside the talented team at Elsie to accelerate a next-generation oligonucleotide platform. By bringing together Elsie's expertise and our internal capabilities, we can design and develop oligonucleotides for difficult-to-treat diseases of scale with larger patient populations."

08:06 EDT Banzai signs 169 customers in May - Banzai International announces the addition of 110 new and 59 reactivating customers during May 2024, bringing the total year-to-date sign-ups to 979. "We continue to see customer momentum build as we move through Q2, including adding several new large accounts and key renewals in May," said Joe Davy, CEO and Founder of Banzai. "We've added nearly 1,000 logos this year so far and we look forward to providing our new and current customers with powerful solutions to engage their customers and grow their organizations."

08:05 EDT Katapult launches Katapult Layoff Insurance - Katapult Holdings announced the launch of Katapult Layoff Insurance, powered by Harmonic. This new offering provides a cash benefit of up to $2,000 for customers facing involuntary job loss. For a low monthly payment, Katapult customers can secure this critical financial buffer, enhancing their ability to navigate unexpected financial hardships. Customers can access Katapult Layoff Insurance through Katapult's mobile app and website. Enrollment is immediate, with policyholders becoming eligible for a claim after a 90-day waiting period. This enables customers to claim their benefits quickly and easily by showing proof of eligibility for state unemployment benefits.

08:03 EDT Ocuphire Pharma announces presentations on development of APX3330 - Ocuphire Pharma announced that clinical updates on the Company's lead candidate APX3330 for diabetic retinopathy will be featured in upcoming presentations at the Clinical Trials at the Summit meeting on June 8 in Park City, Utah, and the Retinal Imaging Biomarkers & Endpoints Summit meeting June 25-27 in Boston. APX3330 is an oral small-molecule inhibitor of Ref-1 being developed for the treatment of non-proliferative diabetic retinopathy. DR affects approximately 10 million of the 38 million Americans with diabetes and is the leading cause of blindness in working age adults, and 80 percent of DR patients have NPDR. "Clinical Update on Oral APX3330 for Diabetic Retinopathy" will be presented by Veeral Sheth, M.D., M.B.A., a practicing retina specialist at University Retina and Clinical Assistant Professor at the University of Illinois, at the Clinical Trials at the Summit meeting. Clinical Trials at the Summit brings together a diverse group of experts to discuss ongoing clinical trials and the latest data to accelerate advances in vitreoretinal care. "Multiplex Analysis of Clinical Imaging & Biomarker Data to Validate Novel Endpoints for Diabetic Retinopathy" will be presented by Ashwath Jayagopal, Ph.D., Ocuphire's Chief Scientific and Development Officer, at the second annual Retinal Imaging Biomarkers & Endpoints Summit. The Retinal Imaging Biomarkers & Endpoints Summit is the only industry-dedicated event focusing on streamlining imaging data analysis with the implementation of AI-based predictive measures for earlier detection and diagnosis to optimize patient stratification, selection and recruitment for trials. Ocuphire anticipates initiating the ZETA-2 Phase 2/3 trial of APX3330 for NPDR in early 2025.

08:02 EDT Bitdeer to acquire Desiweminer in all-stock transaction - Bitdeer Technologies Group entered into a share purchase agreement with FreeChain, a fabless crypto ASIC design company, on June 3, 2024 to acquire all of the issued and outstanding shares of Desiweminer for a consideration of 20 million Class A ordinary shares of the Company. A portion of the Bitdeer Shares to be issued pursuant to the Agreement will vest in equal instalments over a period of five or seven years, subject to the terms and conditions therein. Additionally, 50% of the Bitdeer Shares issued to certain sellers under the Agreement cannot be transferred for a period of six months following the closing, and the remaining 50% of the Bitdeer Shares issued to such sellers cannot be transferred for a period of twelve months following the closing. The strategic acquisition, which is subject to customary closing conditions, follows a rigorous ten-month due diligence period, during which Bitdeer thoroughly evaluated Desiweminer's technology, engineering team, and supply chain. Desiweminer's cutting-edge chip designs are highly complementary to those developed by Bitdeer and are ideally suited for advanced semiconductor processes at 4nm and below. With this acquisition, the Desiweminer team will join Bitdeer's ASIC design team in Singapore, further strengthening the Company's capabilities and accelerating its time to market. Products featuring integrated technologies are slated for imminent release.

07:59 EDT Fastenal reports May net sales up 1.5% to $658.72M - Fastenal reported May net sales were up 1.5% from last year to $658.72M and that daily sales were up 1.5% to $29.94M. Reference Link

07:40 EDT Aramark teams with Pringle to deploy autonomous 'floor cleaning robots' - "To improve efficiency and achieve superior cleaning results, Aramark is partnering with Pringle Robotics, a developer of autonomous robotic solutions for facilities management, to install floor cleaning robots and operational software solutions at key customer facilities, it was announced today..."Our clients depend on us to introduce leading technologies that can help to manage their facilities in a way that delivers superior cleaning efficacy with an attractive cost structure," said John Hanner President and CEO of Aramark Facilities Management.

07:39 EDT Moderna's mRNA-3705 selected by FDA for START pilot program - Moderna announced that the U.S. Food and Drug Administration has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics pilot program. mRNA-3705 is an investigational therapeutic for methylmalonic acidemia due to methylmalonic-CoA mutase deficiency. The START pilot program was initiated by the U.S. FDA in September 2023 to accelerate the development of novel treatments addressing unmet medical needs in rare diseases, with an initial selection of up to seven novel treatments, three by the Center for Drug Evaluation and Research and four by the Center for Biologics Evaluation and Research. The milestone-driven initiative is intended to help the progression to pivotal clinical studies or pre-BLA/NDA meeting stages by enhancing communications between manufacturers and the U.S. FDA. Selected manufacturers will benefit from rapid, ad-hoc U.S. FDA interactions to support clinical development, such as study design, patient population, and statistical methods, beyond standard formal meetings. The program is designed to generate high-quality, reliable data to support marketing approvals, ensuring promising treatments advance efficiently through regulatory milestones. mRNA-3705 is being investigated in a Phase 1/2 study, called the "Landmark study," an adaptive, open-label study designed to evaluate the safety and tolerability of the investigational therapeutic administered via intravenous infusion in patients one year and older with isolated MMA due to methylmalonyl-CoA mutase deficiency.

07:37 EDT 4D Molecular presents interim data from Phase 1/2 AEROW trial - 4D Molecular Therapeutics announced positive interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic fibrosis lung disease. Interim data from the study will be presented by Jennifer Taylor-Cousar, M.D., MSCS, in an oral presentation titled, "CFTR transgene expression in airway epithelial cells following aerosolized administration of the AAV-based gene therapy 4D-710 to adults with cystic fibrosis lung disease," at the 47th European Cystic Fibrosis Conference held in Glasgow, UK. "The interim data we shared today from the AEROW clinical trial continues to showcase the breadth and depth of our platform, product engine and pipeline," said David Kirn, M.D., Co-Founder and Chief Executive Officer of 4DMT. "4D-710 is well positioned as the lead program in our pulmonology portfolio as we move into mid to late-stage development. These clinical results also support continued use of our next-generation A101 pulmonary vector for large-market lung diseases such as alpha-1 antitrypsin deficiency lung disease, for which we are developing 4D-725, an aerosolized genetic medicine currently in IND-enabling preclinical studies."

07:37 EDT Research Frontiers, AIT Group introduce retrofittable SPD-SmartGlass window - Research Frontiers and AIT Group announced the introduction of a retrofittable SPD-SmartGlass window. Introducing the Thermolite RetroWAL SPD system, this product will be unveiled for the first time at the AIA Expo 2024 in Washington, DC, from June 6-7, 2024, at Booth 720 The companies said, "Imagine a light-control film laminated inside of glass or plastic that allows users to instantly change the film's tint from clear to dark or any state in between. This can be done at the touch of a button, speaking to a smart device, in response to commonly-used sensors such as light, motion, or thermostat sensors, or integrated as part of a building's control system. This SPD-Smart film uses specially-engineered nanoparticles suspended and distributed throughout the flexible film to accomplish this. While it might sound futuristic, it has been used reliably to replace aircraft window shades since 2001, and has been in tens of thousands of vehicles by Mercedes, McLaren, Cadillac and Ferrari since 2011. It has also been featured in yachts, cruise ships, trains, buses, museums, augmented reality windshields, heads-up displays, and architectural applications such as a 10,000 square foot roof at the 2015 World's Fair in Milan. Building and vehicle occupants can instantly change the tint of their windows or sunroofs to help keep out harsh sunlight and heat, while at the same time creating an open-air feeling even when the window or sunroof is closed. Glass or plastic using Research Frontiers' patented SPD-SmartGlass technology effectively blocks UV and infrared rays in both clear and darkly tinted modes, helping keep interiors cooler, and protecting occupants and interiors while also enhancing security, comfort and privacy. In vehicles such as cars and trains, some of the other benefits of SPD-SmartGlass include significant heat reduction inside the vehicle, UV protection, glare control, reduced noise, and reduced fuel consumption. Independent calculations also show that the use of SPD-SmartGlass can reduce CO2 emissions by four grams per kilometer, and increase the driving range of electric vehicles by approximately 5.5 percent. Now, for the first time, this advanced technology is available in a format that can be retrofitted into existing structures. This development is a game-changer for property owners looking to upgrade their buildings with modern, energy-efficient solutions without the need for complete window replacements. AIT Group's expertise in laminated glass ensures that the retrofitable SPD-SmartGlass windows are durable, aesthetically pleasing, and easy to install."

07:34 EDT Vishay acquires Ametherm for $31.5M in cash - Vishay Intertechnology has acquired Ametherm, Inc., a leader in inrush current limiters and sensing thermistors, for approximately $31.5 million in cash. Ametherm specializes in precision thermistors for inrush current limiters and temperature sensing that come in various sizes, forms and packages to meet the demands of the automotive, industrial, aerospace/defense and medical markets. The company offers the highest-rated NTC and PTC thermistors in customizable versions to meet the needs of specific applications for circuit protection.

07:33 EDT FirstService's Roofing Corp of America acquires Crowther, Hamilton - FirstService Corporation announced that its subsidiary, Roofing Corp of America, has acquired Crowther Roofing and Cooling and Hamilton Roofing. The additions of Crowther and Hamilton provide RCA with a strong new presence in the important Florida market and will collectively add more than $150 million in annual revenues. The existing management teams of both businesses have retained minority equity interests and will continue to oversee their respective day-to-day operations. Terms of the two transactions were not disclosed. Headquartered in Fort Myers, Florida and founded in 1974, Crowther is the leading roofing services provider in Southwest Florida, with a particular focus on the commercial end market. Crowther also provides complementary HVAC maintenance and mechanical contracting services. Crowther operates from three regional branch locations and employs approximately 750 roofing installation and service technicians. Established in 1983 with its head office in Malabar, Florida, Hamilton is the leading provider of commercial roofing services across Eastern Florida's Space Coast. Hamilton has developed long-established relationships with major blue-chip commercial clients spanning the government, aerospace and education sectors.

07:23 EDT Moderna says mRNA-3705 selected by FDA for START pilot program - Moderna announced that the Food and Drug Administration has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics, or "START," pilot program. mRNA-3705 is an investigational therapeutic for methylmalonic acidemia, or MMA, due to methylmalonic-CoA mutase deficiency. "We are excited about this opportunity and proud that our investigational mRNA therapeutic for MMA was selected by the U.S. FDA for the START pilot program. This selection highlights the promise of Moderna's innovative mRNA platform beyond vaccines and the potential this novel medicine may have in addressing the serious and unmet medical needs of MMA. Selection for this program will enable enhanced communication with the U.S. FDA, resulting in acceleration of our development program as we prepare for pivotal study initiation for mRNA-3705 in 2024," said Kyle Holen, M.D., Moderna's Senior Vice President and Head of Development, Therapeutics and Oncology.

07:18 EDT Alta Global partners with MMA coach Eric Nicksick - Alta Global Group announces its partnership with legendary MMA coach Eric Nicksick, renowned for guiding three fighters to UFC championships, including Francis Ngannou, Aljamain Sterling, and Sean Strickland. This strategic alliance is set to deepen Alta's connection with MMA's 640 million fans and convert fandom into active participation through its digital platform and in gym training programs.

07:17 EDT CollPlant bio-prints 200cc commercial-size regenerative breast implants - CollPlant Biotechnologies has successfully printed for the first-time breast implants of 200 cc, which are commercial size. These implants were printed using CollPlant's proprietary rhCollagen bioinks. In addition, CollPlant announced additional, positive, interim preclinical data from ongoing large-animal studies, evaluating its regenerative breast implants. Currently there are no other commercial products that allow regeneration of soft tissues such as the breast. Additional positive data from CollPlant's pre-clinical studies that are currently underway show evidence of well-developed connective tissue containing blood vessels within the implant. An initial biodegradation process was observed, while preserving the original structure of the 3D breast implant. No adverse tissue reaction was observed. The most common breast augmentation or reconstruction procedures today are based on synthetic silicone breast implantations, an artificial substitution for natural regenerated tissue with risks of complications. CollPlant's rhCollagen-based, 3D-bioprinted breast implants are expected to regenerate breast tissue without eliciting immune response. In addition, CollPlant's regenerative breast implants have the potential to provide a novel solution for women in the need for breast reconstruction and augmentation. CollPlant expects to report topline data from an additional large-animal study to evaluate commercial-size versions of the 3D-bioprinted, regenerative breast implants, and an additional ongoing study, in Q4 of this year and Q1 of next year.

07:16 EDT G-III Apparel in strategic partnership with AWWG for ownership stake of ~12% - G-III Apparel Group announced a strategic partnership and investment in All We Wear Group AWWG or Group for an ownership stake of approximately 12%. AWWG now becomes the Agent for DKNY, Donna Karan and Karl Lagerfeld across Spain and Portugal. Madrid-based AWWG, which is owned by M1 Group, LCatterton and founder Carlos Ortega, is a premier platform for international brands including Hackett, Pepe Jeans and Faconnable, and generates over $650 million in revenues across over 3,500 points of sale in over 86 countries. The Group, which also manages the Iberian business for PVH Corp., offers significant expertise to unlock the Spain and Portugal markets for G-III's brands as the Company seeks to maximize its European growth opportunity. Additionally, G-III plans to leverage AWWG's notable presence in India to expand its key brands, led by DKNY, in one of the fastest growing fashion markets in the world. In turn, AWWG will benefit from G-III's best-in-class operations in North America to expand their footprint in the market. Morris Goldfarb, G-III's Chairman and Chief Executive Officer, said, "This exciting partnership with AWWG helps us accelerate a number of our strategic priorities. It not only affords us the opportunity to meaningfully invest in a company with iconic brands, but also represents a sizable international presence with a strong infrastructure and talented leadership team that will benefit our efforts to scale our European business. At the same time, we look forward to supporting AWWG's overall growth and advancement of their brands here in North America."

07:13 EDT J.M. Smucker sees FY25 CapEx $450M - Sees FY25 adjusted effective tax rate 24.4%.

07:11 EDT Radcom secures over $45M in new contracts since start of 2024 - Radcom announced that it has secured over $45M in new contracts since the beginning of 2024. This significant achievement validates the company's strategy for growing the business and increasing revenue through Radcom's innovative solutions, especially with the transition to 5G and cloud-based networks.

07:10 EDT Tilray announces launch of Purple Churro by Redecan cannabis - Tilray Brands announced the launch of 'Purple Churro,' by Redecan cannabis - a new sativa making its debut. "This unique strain offers a sweet, indulgent experience with a potent twist and boasting THC levels, marking yet another commitment to innovation with brand new genetics joining Redecan's high quality flower lineup," the company said.

07:10 EDT Cartesian Therapeutics announces employee inducement grant - Cartesian Therapeutics announced the granting of an inducement award to a new employee. On June 3, 2024, the Company issued to this employee an option to purchase 11,000 shares of the Company's common stock with an exercise price of $36.00, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company's board of directors. The option vests as to 25% on June 3, 2025, and then in three equal annual installments thereafter such that the option will be fully vested on June 3, 2028. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee's entry into employment with the Company.

07:09 EDT D-Wave Quantum extends agreement with Aramco - D-Wave Quantum announced that it has extended its agreement with Aramco, a global integrated energy and chemicals company, to manage geophysical optimization problems through quantum technologies. Aramco Research Center in Delft, the Netherlands, is focused on developing advanced computing technologies to help address global energy challenges. For the past two years, it has been working with D-Wave's powerful quantum technologies on solving highly complex optimization problems involved in computationally intensive seismic imaging, an ultrasound-like technology used to map the various geological strata many kilometers beneath the surface. With support from D-Wave, the team has been able to create its first subsurface maps, using tens of gigabytes of seismic data as input, with the aim of processing a terabyte of seismic data with the D-Wave quantum computer in 2024. Using D-Wave's quantum computers and hybrid solvers, accessible through the Leap quantum cloud service, Aramco's team of researchers developed their own hybrid classical-quantum geophysical applications. Using D-Wave's quantum technologies, the Center has seen performance gains over classical computers in both time-to-solution and scale.

07:09 EDT Syndax to advance into Phase 1b portion of trial evaluating revumenib - Syndax Pharmaceuticals announced that it has advanced into the Phase 1b portion of its Phase 1/2 proof-of-concept trial of revumenib, the company's highly selective, oral menin inhibitor, as a monotherapy in patients with relapsed or refractory metastatic microsatellite stable colorectal cancer. The company's decision was supported by the trial's Independent Data Monitoring Committee following its recent pre-planned review of initial data from the Phase 1a portion of the trial.

07:08 EDT B2Gold, Sandbox Royalties partner to create Versamet Royalties - B2Gold announces that it has entered into a purchase and sale agreement to sell a portfolio of 10 precious and base metals royalties to Sandbox Royalties Corp, a private, returns-focused metals royalty company. In connection with the Transaction, Sandbox has been renamed Versamet Royalties Corporation. All dollar figures are in United States dollars unless otherwise indicated. Under the terms of the Agreement, Versamet will acquire ownership of the Royalties and as consideration will issue 153.2 million common shares to B2Gold at a price of C$0.80 per share, representing an equity ownership interest in Versamet of 33.0% valued at approximately $90 million. "This strategic partnership provides B2Gold with an attractive opportunity to unlock the value of our royalties which have gone largely unrecognized by the market and were not a core part of our business," said Clive Johnson, President and CEO of B2Gold. "As a significant shareholder, B2Gold is pleased to retain meaningful upside exposure and leverage to Versamet as its experienced management team stewards its strengthened asset base and continues executing on its growth strategy to create future shareholder value."

07:07 EDT Relay Therapeutics expects cash to fund operations into second half of 2026 - The three new programs disclosed today are from Relay Therapeutics' existing pre-clinical pipeline. The continued advancement of these programs has already been accounted for in the company's existing cash runway guidance. As of March 31, 2024, cash, cash equivalents and investments totaled approximately $750 million and are expected to fund the current operating plan into the second half of 2026.

07:06 EDT Relay Therapeutics announces anticipated milestones - Breast Cancer: RLY-2608 + fulvestrant data update in the fourth quarter of 2024; RLY-2608 + fulvestrant + ribociclib initial safety data in the fourth quarter of 2024; RLY-2608 + fulvestrant + atirmociclib clinical trial initiation by the end of 2024; RLY-2608 + fulvestrant potential Phase 3 trial initiation in 2025. Genetic Disease: Vascular malformations: RLY-2608 clinical trial initiation in the first quarter of 2025; Fabry disease: clinical start in the second half of 2025. Precision Oncology: Lirafugratinib: tumor agnostic data and regulatory update in the second half of 2024; NRAS: clinical start in the second half of 2025

07:05 EDT Big Lots sees Q2 comparable sales down in mid- to high-single digits y-o-y - Expects gross margin rate to improve significantly vs. the prior year, and be up by at least 300 basis points, resulting in a year-over-year improvement in gross margin. Expects adjusted SG&A dollars down in the low to mid-single-digit percentage range versus 2023. Does not expect to recognize any tax benefit in Q2 as management expects to remain in a three-year cumulative loss position, which requires the company to record valuation allowances against deferred tax assets, including those related to net operating losses. The company is not providing EPS guidance but expects its Q2 adjusted operating loss to be better than last year.

07:04 EDT Chemomab Therapeutics presents data on clinical potential of CM-101 - Chemomab Therapeutics reported that it presented two scientific posters supporting the clinical rationale for the company's primary sclerosing cholangitis program at EASL 2024, the Annual Congress of the European Association for the Study of the Liver, which is taking place June 5-8, 2024 in Milan, Italy. The first EASL poster describes an ex vivo-developed translational assay designed to further characterize the anti-fibrotic activity of CM-101 in patients with liver disease. Using a serum-based ex vivo hepatic stellae cell activation assay derived from patients with liver fibrosis due to metabolic dysfunction-associated steatohepatitis, the study showed that sera from these patients directly activates HSCs and that HSC activation levels were significantly reduced in the sera of patients treated with CM-101. These findings support CM-101's mode of action in liver fibrosis and are expected to help in characterizing its anti-fibrotic drug effects by serving as a translational tool in PSC clinical trials. In a second poster, researchers presented a comprehensive proteomic profiling study of patients with PSC, which was combined with machine learning-based methods to develop a protein signature model that successfully predicted the presence and severity of PSC when combined with proteins correlated with the Enhanced Liver Function biomarker score. The machine learning analysis was also able to identify key proteins associated with PSC progression. Additionally, the model showed that high CCL24 levels were associated with cirrhosis in patients with PSC.

07:02 EDT FTAI Aviation, IAE sign strategic V2500 engine maintenance services agreement - FTAI Aviation and IAE International Aero Engines AG announced a five-year EngineWise maintenance services agreement for V2500 engines. The agreement includes over 100 full performance restoration shop visits. "We look forward to collaborating with IAE to restore these engines together," said Joe Adams, CEO, FTAI Aviation. "We are committed to the V2500 engine and see tremendous demand for it in the next decade. Teaming up with IAE allows us to extend the life of the V2500 fleet while providing flexible engine power to our airline customers."

06:56 EDT Aecom-led JV selected to provide facility support services for U.S. Navy - Aecom announced that an Aecom-led joint venture with Akima Support Operations has been selected by the Naval Facilities Engineering Systems Command Pacific to deliver facility support services under the Global Contingency Services Multiple Award Contract. This is Aecom's third consecutive GCSMAC award. Under this multiple-award, indefinite-delivery, indefinite-quantity contract, the joint venture will provide various services in response to natural disasters, humanitarian efforts, Navy operations and projects worldwide.

06:51 EDT The Buckle reports May SSS down 7.6% - The Buckle announced that comparable store net sales, for stores open at least one year, for the 4-week period ended June 1, 2024 decreased 7.6 percent from comparable store net sales for the 4-week period ended June 3, 2023. Net sales for the 4-week fiscal month ended June 1, 2024 decreased 8.2 percent to $82.0 million from net sales of $89.3 million for the prior year 4-week fiscal month ended May 27, 2023. Comparable store net sales year-to-date for the 17-week period ended June 1, 2024 decreased 8.6 percent from comparable store net sales for the 17-week period ended June 3, 2023. Net sales for the 17-week fiscal period ended June 1, 2024 decreased 7.4 percent to $344.5 million compared to net sales of $372.1 million for the prior year 17-week fiscal period ended May 27, 2023. Due to the 53rd week in fiscal 2023, comparable store net sales for the month and year-to-date periods are compared to the 4-week and 17-week periods ended June 3, 2023.

06:49 EDT nVent Electric affiliate acquires majority interest in Trachte for $695M - Palladium Equity Partners announced that it has signed a definitive agreement under which it will sell its majority interest in Trachte, a provider of highly engineered protection and control buildings with mission critical applications, to an affiliate of nVent Electric for $695M. Palladium, which focuses on transforming family and founder-owned businesses, acquired its majority stake in Trachte in 2020.

06:34 EDT Freight Technologies adds 26 new customers, 149 new carriers in 2024 - Freight Technologies is proud to announce it has on-boarded 26 new customers and 149 new carriers to its platform year-to-date. The roster of new customers extends Fr8Tech's footprint across its core markets and its service offerings, especially its US domestic and US-Mexico cross-border spot services and the company's Fr8Fleet dedicated capacity services, a highly valued offering for large enterprise customers primarily in the Mexican domestic market. A few such companies that Fr8Tech has added in 2024 thus far are Grupo Solave, Argos Electrica, Aqua-Aid Inc, and AR Brokers LLC.

06:31 EDT nVent Electric to acquire Trachte for $695M - nVent Electric has entered into a definitive agreement to acquire the parent of Trachte for a purchase price of $695M, subject to customary adjustments. Trachte is a manufacturer of custom-engineered control building solutions designed to protect critical infrastructure assets. Trachte is headquartered in Madison, Wisconsin with more than 500 employees. Trachte estimates 2024 revenues to be approximately $250M. nVent expects the acquisition to be accretive to adjusted EPS in the first year following completion of the transaction. The effective enterprise value multiple is ~12x anticipated Trachte 2024 adjusted EBITDA. The transaction is expected to close in Q3, subject to customary conditions, including regulatory approval. nVent expects to fund the acquisition with a combination of available cash on hand and new debt. Upon closing of this transaction, nVent plans to operate Trachte within its Enclosures segment.

06:18 EDT Vista Outdoor receives increased acquisition offer from MNC Capital - Vista has received an increased all-cash proposal from MNC Capital Partners to acquire all of the outstanding shares of Vista for $39.50 per share, or over $3.0B. The revised proposal represents a premium of 46% to the VWAP to the last closing price before MNC's initial offer on February 19. The revised offer is also an over 30% premium to the last closing price prior to MNC's initial offer. Additionally, the latest offer implies a value for Revelyst of over $1B, as compared to Vista's valuation for Revelyst of $570M in its own investor presentation on February 1. MNC's revised offer is based on the Transaction Expenses being $50M, and will be adjusted up or down based on the actual amount of Transaction Expenses. MNC believes that absent its interest in an acquisition, Vista's share price would trade back to where it was prior to MNC's initial offer, which was below $30.00 per share. MNC's revised proposal is not subject to any financing condition and the financing structure remains the same.

06:15 EDT Noyb urges 11 DPAs to immediately stop Meta's 'abuse of personal data for AI' - The Noyb-European Center for Digital Rights, a Vienna-based nongovernmental organization, said Thursday that it filed complaints with data-protection authorities in Germany, France, Italy, Spain and other seven countries over Meta's new AI project. "Over the past few days, Meta has informed millions of Europeans that its privacy policy is changing once again. Only on closer inspection of the links in the notification did it become clear that the company plans to use years of personal posts, private images or online tracking data for an undefined 'AI technology' that can ingest personal data from any source and share any information with undefined 'third parties.' Instead of asking users for their consent, Meta argues that it has a legitimate interest that overrides the fundamental right to data protection and privacy of European users. Once their data in the system, users seem to have no option of ever having it removed. noyb has now filed complaints in 11 European countries, asking the authorities to launch an urgency procedure to stop this change immediately, before it comes into force on 26 June 2024." noyb said it plans to file complaints in the remaining EU Member States in the coming days. Reference Link

06:04 EDT Zura Bio forms Scientific Advisory Board with leading experts - Zura Bio announced the formation of a Scientific Advisory Board with leading experts from rheumatology, dermatology, and immunology. The five distinguished founding members of the SAB are Johann Gudjonsson, M.D, Ph.D., Dinesh Khanna, M.D., M.Sc., Ajay Nirula, M.D., Ph.D., Michael Weinblatt, M.D. and Steven Ziegler, Ph.D. "With the launch of the SAB, we are strengthening our commitment to advancing solutions in translational and clinical science across our portfolio," stated Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine.

06:03 EDT New Found Gold settles litigation with ThreeD Capital - New Found Gold announces that it has entered into a settlement agreement with respect to the lawsuit filed by ThreeD Capital and 1313366 Ontario against New Found, Palisades Goldcorp andCollin Kettell in the Ontario Superior Court of Justice. The Settlement Agreement resolves the Lawsuit completely and avoids the expense, burden and uncertainty associated with litigation. The settlement of the Lawsuit also allows New Found to focus on its business without distraction related to the Lawsuit, which had been scheduled for trial in January 2025. Pursuant to the Settlement Agreement, the Plaintiffs will receive a total of 3,750,000 common shares of New Found from the Defendants. Palisades will transfer 2,607,434 New Found Shares that it currently owns to ThreeD and 772,566 New Found Shares that it currently owns to 131. New Found will issue 285,429 New Found Shares to ThreeD and 84,571 New Found Shares to 131, subject to the approval of the TSX Venture Exchange and the NYSE American. All of the New Found Shares received by the Plaintiffs will be subject to a four month hold period, unless an exemption is available under applicable securities legislation. The Settlement Agreement does not include any admission of liability and provides for fulsome releases by the Plaintiffs to the Defendants.

05:53 EDT Bloom Energy enters collaboration with Sembcorp - Bloom Energy announced a collaboration with Sembcorp at the sidelines of the 2024 Clean Economy Investor Forum, organized under the auspices of the Indo-Pacific Economic Framework, or IPEF. The Bloom-Sembcorp collaboration will involve Sembcorp's potential utilization of Bloom's proprietary solid oxide fuel cell technology and third-party proven carbon capture technologies to produce reliable, low-carbon electricity to meet Singapore's changing energy needs. This collaboration aligns with Singapore's recent launch of the Green Data Centre Roadmap, where one of the goals is to develop sustainable data centers with a greater use of green energy. Bloom's fuel cell Energy Server product, when integrated with carbon capture, will provide low-carbon power to the data centers. The same system can potentially deliver green energy in the future, tapping on low-carbon feedstock. The Energy Servers can also be deployed as a grid parallel system in conjunction with utility power, mitigating grid constraints. Headquartered in Singapore, Sembcorp has a balanced energy portfolio of 21.2GW, including 14.4GW of gross renewable energy capacity, across 10 countries. The company delivers sustainable solutions to drive energy transition by leveraging its sector expertise and global track record.

05:13 EDT Sonoco Products to raise tube, core grades prices in EMEA - Sonoco-Alcore announced that due to continued inflationary pressure on the business, it will raise prices by 7% on all tube and core grades sold in the company's EMEA regions. The increase is in direct response to the continued escalation of its cost base and will be effective for all shipments made on or after June 15.

05:06 EDT Gilead publishes MYR204 study data in New England Journal of Medicine - Gilead announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a, or PegIFN, in adults living with compensated chronic hepatitis delta virus, or HDV, infection. Published in the New England Journal of Medicine, or NEJM, the data demonstrate that the investigational combination of bulevirtide 10 mg with PegIFN was superior to investigational bulevirtide 10 mg monotherapy in achieving undetectable HDV RNA at Week 24 after the end of treatment, or EOT. The end of study data presented at the European Association for the Study of the Liver, or EASL, Congress 2024, demonstrate that treatment with bulevirtide 10 mg in combination with PegIFN maintained a 46% rate of undetectable HDV RNA at Week 48 after EOT, confirming its potential as a finite therapy for adults living with chronic HDV. HDV affects an estimated 5% of people living with chronic hepatitis B, or HBV, with a global prevalence of more than 12M people. Data published in NEJM demonstrate that at Week 24 after EOT, undetectable HDV RNA was achieved by 32% and 46% of patients taking bulevirtide 2 mg in combination with PegIFN and bulevirtide 10 mg in combination with PegIFN, respectively. In the monotherapy groups, PegIFN monotherapy and bulevirtide 10 mg monotherapy, undetectable HDV RNA was achieved by 17% and 12%, respectively. The safety profiles of bulevirtide in combination with PegIFN were consistent with those of the individual components. The most frequent adverse events were leukopenia, neutropenia and thrombocytopenia, and most were mild to moderate. Data presented at EASL demonstrate that at Week 48 after EOT, undetectable HDV RNA was achieved by 26% and 46% of patients taking bulevirtide 2 mg in combination with PegIFN and bulevirtide 10 mg in combination with PegIFN, respectively. In the monotherapy groups, PegIFN monotherapy and bulevirtide 10 mg monotherapy, undetectable HDV RNA was achieved by 25% and 12%, respectively. Also at EASL, late-breaking data on the pivotal Phase 3 MYR301 study evaluating bulevirtide as monotherapy for the treatment of adults with chronic HDV infection were also presented and reinforced bulevirtide as an efficacious and generally well-tolerated long-term treatment option. Patients had similar rates of combined response at Week 144 compared to Week 96, with 57% and 54%, respectively, among those receiving bulevirtide 2 mg or 10 mg. This is consistent with and builds on the data shared at EASL 2023. Bulevirtide continued to be generally well-tolerated through Week 144, and the safety profile was similar between the bulevirtide 2 mg and 10 mg treatment arms, with the study investigators attributing no serious adverse events to bulevirtide treatment. Through 144 weeks of treatment, dose-dependent increases in bile acids remained asymptomatic, were not associated with any clinical sequelae and did not result in any discontinuations or treatment interruption.